Scholars Central

Conference abstractPublished 11 Apr 2022

Prostate cancer biomarker: from bench to clinic

Authors: Jianqing Lin

Washington University School of Medicine and Health Sciences, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

There are several prognostic models for predicting overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor cell (CTCs) enumeration at baseline and its conversion post systemic treatment are the most accurate and independent predictor of OS in mCRPC. This talk will cover the biomarker aspect of mCRPC patients CTCs and current research related to its predictive value of CTCs AR-V7 analysis in selecting novel androgen receptor signaling inhibitors, prognostic value of CTC cluster; CTCs heterogeneity and future adaptive therapeutic selection based on single cell CTC genomic and transcriptomes analysis. In the predictive biomarker front, clinical utility of the analysis of AR-V7, DNA damage repair pathway gene, PSMA, tumor mutation burden and MSI status in prostate cancer will be discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Jianqing Lin”